Howe & Rusling’s Esperion Therapeutics ESPR Stock Holding History

Howe & Rusling’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-100	Closed	-$1K	–	1027
2021 Q4	$1K	Buy	+100	New	+$801	﹤0.01%	924

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Howe & Rusling's ESPR Position: Q1 2022 in Review

Howe & Rusling sold out of Esperion Therapeutics (ESPR) in Q1 2022, closing a stake of 100 shares — an estimated $1K sold.

Howe & Rusling first reported a position in ESPR in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 132 funds tracked by Wall St. Rank hold ESPR as of Q1 2022.

Howe & Rusling reported no remaining Esperion Therapeutics position as of Q1 2022 after selling out during the quarter.
Howe & Rusling sold 100 Esperion Therapeutics shares in Q1 2022, an estimated $1K.
Howe & Rusling first reported a position in Esperion Therapeutics in Q4 2021 and held it in 1 quarter.
Howe & Rusling's Esperion Therapeutics position peaked at $1K in Q4 2021.
132 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2022.

Based on Howe & Rusling's 13F filing for Q1 2022, filed 10 May 2022.